Dordaviprone
Modeyso · Imipridone (ONC201; DRD2/ClpP)
2025 imipridone for H3 K27M glioma; renally well tolerated — QT prolongation, not nephrotoxicity, is the safety focus.
Lymphir · DENI
Immunotoxin (IL-2–diphtheria) · approved 2024 · 8 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
An IL-2/diphtheria-toxin fusion whose capillary-leak syndrome drives prerenal AKI — check albumin before every cycle.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Capillary-leak syndrome (CLS) occurred in ~20.3% (grade >=3 ~5.8%) in the 2024 denileukin diftitox-cxdl trial. With the original formulation hypoalbuminemia was very common (~79%, ~15% grade 3/4) and a vascular-leak syndrome occurred in roughly a quarter of patients. AKI here is prerenal/hemodynamic rather than a quantified direct renal injury rate.Source: Foss et al., J Clin Oncol 2024 (20.3% capillary-leak syndrome; attributable AKI rate not separately quantified)
Acute, peri-infusion over the first one to two cycles (capillary-leak prerenal AKI); generally not cumulative.
Distilled from: “Acute, peri-infusion (first 1-2 cycles); generally not cumulative.”
This agent's defining kidney lesion — its #1 signature. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Engineered fusion protein joining interleukin-2 to the catalytic and translocation fragments of diphtheria toxin (DAB389IL-2). IL-2 binds the high-affinity IL-2 receptor (CD25/IL-2R-alpha) on malignant T cells; after internalization the diphtheria-toxin fragment ADP-ribosylates elongation factor 2, halting protein synthesis and causing apoptosis.
Vasculature / Endothelium
Glomerular & peritubular capillaries
7 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Quoted verbatim from this agent's current FDA label (Jan 2025) — not paraphrased or interpreted. Full label on DailyMed .
Boxed warning
WARNING: CAPILLARY LEAK SYNDROME Capillary leak syndrome (CLS), including life-threatening or fatal reactions, can occur in patients receiving LYMPHIR. Monitor patients for signs and symptoms of CLS during treatment. Withhold LYMPHIR until CLS resolves, or permanently discontinue based on severity [see Dosage and Administration ( 2.1 , 2.4 ) and Warnings and Precautions ( 5.1 )] . WARNING: CAPILLARY LEAK SYNDROME See full prescribing information for complete boxed warning. Capillary leak syndrome (CLS), including life-threatening or fatal reactions, can occur in patients receiving LYMPHIR. Monitor patients for signs and symptoms of CLS during treatment. Withhold LYMPHIR until CLS resolves or permanently discontinue based on severity. ( 2.1 , 2.4 , 5.1 )
Kidney rows of the label's dosage tables
From the LYMPHIR label (Jan 2025) · DailyMed
No row of this label's 3 dosage tables names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.
Everything below is FAERS — adverse events someone chose to report, about 60 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
16 of 60 reports
Reported with hospitalization
16 of 60 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 2 of the 60 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Denileukin diftitox sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Modeyso · Imipridone (ONC201; DRD2/ClpP)
2025 imipridone for H3 K27M glioma; renally well tolerated — QT prolongation, not nephrotoxicity, is the safety focus.
Zenbexus · Cereblon E3 ligase modulator (CELMoD)
2026 first-in-class CELMoD; no attributable lesion (renal impairment 11% vs 8% on the comparator arm) but exposure rises 1.8x below eGFR 30 off dialysis.
HIF-2α inhibitor (investigational)
Trial-stage RCC HIF-2α inhibitor; renal profile being defined.
Welireg · HIF-2α inhibitor
Anemia/hypoxia; emerging renal profile in VHL/RCC.
Vyloy · Anti-Claudin-18.2 monoclonal antibody
2024 gastric mAb; severe on-target nausea/vomiting → volume-depletion prerenal AKI.
Kimmtrak · Bispecific T-cell engager (gp100×CD3 ImmTAC)
CRS-driven hypotension → prerenal AKI early in dosing; uveal melanoma.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.